MUSCLE INVASIVE BLADDER CANCER (MIBC)
Clinical trials for MUSCLE INVASIVE BLADDER CANCER (MIBC) explained in plain language.
Never miss a new study
Get alerted when new MUSCLE INVASIVE BLADDER CANCER (MIBC) trials appear
Sign up with your email to follow new studies for MUSCLE INVASIVE BLADDER CANCER (MIBC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New approach aims to save bladders while fighting aggressive cancer
Disease control Recruiting nowThis study is testing whether a combination of three drugs given before surgery can effectively treat HER2-positive muscle-invasive bladder cancer while allowing patients to keep their bladder. The treatment involves two targeted drugs plus chemotherapy, followed by maintenance t…
Matched conditions: MUSCLE INVASIVE BLADDER CANCER (MIBC)
Phase: PHASE2 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Could simple IV fluids at home keep bladder cancer patients out of the hospital?
Disease control Recruiting nowThis study is testing whether giving patients IV fluids at home after major bladder cancer surgery helps them recover better and avoid being readmitted to the hospital. About 130 patients at Johns Hopkins will be randomly assigned to either receive the home IV fluid program along…
Matched conditions: MUSCLE INVASIVE BLADDER CANCER (MIBC)
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Targeted radiation therapy tested for Tough-to-Treat cancers
Disease control Recruiting nowThis study is testing a two-part approach for people with advanced cancers that cannot be removed by surgery. First, a special imaging scan is used to see if a tumor has a specific target. If it does, a targeted radiation treatment is given to try to control the cancer. The main …
Matched conditions: MUSCLE INVASIVE BLADDER CANCER (MIBC)
Phase: PHASE1, PHASE2 • Sponsor: ITM Oncologics GmbH • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC